Lumito

Executive Summary

Lumito is a Swedish diagnostics company developing ultra-sensitive tissue analysis technology for detecting ultralow biomarker expression, with initial focus on HER2 in breast cancer. Its proprietary nanoparticle-based imaging platform uses photon-upconverting labels to achieve single-molecule sensitivity and wide dynamic range, enabling objective quantification of biomarkers that are undetectable by current methods. This addresses a critical clinical need for identifying patients with HER2 ultralow expression who may benefit from novel targeted therapies. The company is private and has not disclosed funding or revenue, but its technology has been presented at conferences and in white papers. Lumito's approach could disrupt the immunohistochemistry market by providing more accurate and reproducible results, potentially improving patient stratification for therapies like antibody-drug conjugates. Key challenges include commercial adoption and regulatory hurdles. The conviction score of 65 reflects promising technology but limited visibility into commercial traction and financials.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) clearance for HER2 detection assay40% success
• H1 2026Strategic partnership with major pharma or diagnostics company50% success
• Q4 2025Publication of clinical validation study in peer-reviewed journal70% success